2. Academic Validation
  3. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity"

Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "Diabesity"

  • J Med Chem. 2022 Apr 14;65(7):5449-5461. doi: 10.1021/acs.jmedchem.1c01842.
Juan M Decara 1,  Henar Vázquez-Villa 2,  José Brea 3,  Mónica Alonso 1,  Raj Kamal Srivastava 4,  Laura Orio 5,  Francisco Alén 5,  Juan Suárez 1,  Elena Baixeras 1,  Javier García-Cárceles 2,  Andrea Escobar-Peña 2,  Beat Lutz 4,  Ramón Rodríguez 6,  Eva Codesido 6,  F Javier Garcia-Ladona 7,  Teresa A Bennett 8,  Juan A Ballesteros 8,  Jacobo Cruces 6,  María I Loza 3,  Bellinda Benhamú 2,  Fernando Rodríguez de Fonseca 1 5,  María L López-Rodríguez 2
Affiliations

Affiliations

  • 1 Unidad de Gestión Clínica de Salud Mental, Instituto IBIMA, Hospital Regional Universitario, Málaga E-29010, Spain.
  • 2 Departamento de Química Orgánica, Universidad Complutense de Madrid, Madrid E-28040, Spain.
  • 3 Biofarma Research group, USEF Screening Platform, CIMUS, USC, Santiago de Compostela E-15782, Spain.
  • 4 Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg, University of Mainz, Mainz 55128, Germany.
  • 5 Departamento de Psicobiología, Facultad de Psicología, Universidad Complutense de Madrid, Madrid E-28040, Spain.
  • 6 Galchimia, O Pino, A Coruña E-15823, Spain.
  • 7 ABAXYS Therapeutics, Rue du Berceau, 91, Villers-la-Ville 1495, Belgium.
  • 8 ViviaBiotech S.L., Parque Científico de Madrid, Madrid E-28760, Spain.
PMID: 35349261 DOI: 10.1021/acs.jmedchem.1c01842
Abstract

Peptidic agonists of the glucagon-like peptide-1 receptor (GLP-1R) have gained a prominent role in the therapy of type-2 diabetes and are being considered for reducing food intake in obesity. Potential advantages of small molecules acting as positive allosteric modulators (PAMs) of GLP-1R, including oral administration and reduced unwanted effects, could improve the utility of this class of drugs. Here, we describe the discovery of compound 9 (4-{[1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)piperidin-3-yl]methyl}morpholine, V-0219) that exhibits enhanced efficacy of GLP-1R stimulation, subnanomolar potency in the potentiation of Insulin secretion, and no significant off-target activities. The identified GLP-1R PAM shows a remarkable in vivo activity, reducing food intake and improving glucose handling in normal and diabetic rodents. Enantioselective synthesis revealed oral efficacy for (S)-9 in animal models. Compound 9 behavior bolsters the interest of a small-molecule PAM of GLP-1R as a promising therapeutic approach for the increasingly prevalent obesity-associated diabetes.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z